Buy CJC 1295 Without DAC 10mg

Direct Answer: Sourcing CJC-1295 Without DAC 10mg for Laboratory Research

Investigators looking to buy CJC 1295 without DAC 10mg require high-purity, sequence-verified lyophilized peptide for precise experimental design. CJC-1295 Without DAC, technically designated as Modified GRF (1-29), is a 29-amino-acid tetrasubstituted peptide analog of endogenous growth hormone-releasing hormone (GHRH). It is engineered to stimulate pulsatile growth hormone (GH) secretion in preclinical models while exhibiting improved enzymatic resistance compared to native native sequences.

When purchasing this compound, institutional researchers require verifiable analytical data. PX1 Research manufactures CJC-1295 Without DAC 10mg in USA-based, GMP-compliant facilities. Every batch undergoes comprehensive testing in an ISO 17025 accredited laboratory, guaranteeing greater than 98% purity confirmed via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). Each 10mg vial is shipped direct from facilities in California and Arizona with lot-specific Certificates of Analysis (COA) included.

Molecular Structure and Chemical Modifications of Modified GRF (1-29)

Endogenous growth hormone-releasing hormone (GHRH 1-44) possesses a short biological half-life in physiological systems, rapidly degraded by circulating enzymes such as dipeptidyl peptidase IV (DPP-IV). Studies focusing on the bio-active core identified that the first 29 amino acids—known as Sermorelin acetate—retain full receptor activation capability, though native Sermorelin remains vulnerable to swift enzymatic cleavage at positions 1 and 2.

CJC-1295 Without DAC incorporates four strategic amino acid substitutions into the GRF (1-29) sequence to enhance structural stability without incorporating the Drug Affinity Complex (DAC) maleimide moiety. These specific substitutions are D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27. The introduction of D-Alanine at position 2 provides robust steric resistance against DPP-IV cleavage, significantly extending the terminal half-life of the peptide in experimental models while preserving native binding affinity for the GHRH receptor.

Mechanism of Action: Receptor Interactions and Cellular Signaling

At the cellular level, CJC-1295 Without DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a Class B G-protein-coupled receptor primarily expressed on somatotroph cells in the anterior pituitary gland. Binding of the ligand triggers activation of the stimulatory G-protein subunit (Gs), activating adenylate cyclase.

This enzymatic activation converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), driving downstream protein kinase A (PKA) signaling cascades. PKA phosphorylation prompts intracellular calcium influx through L-type voltage-gated calcium channels while inducing transcript factor expression. In preclinical models, this biochemical cascade results in the transcription and exocytosis of growth hormone storage vesicles in a physiological, pulsatile fashion. Researchers interested in structural signaling kinetics can review detailed pathway maps in our peptide research library.

Preclinical Observations: GH Secretion and IGF-1 Modulation

In animal model assays, CJC-1295 Without DAC demonstrates a characteristic pharmacokinetic profile distinct from continuous GH secretagogues. Because the molecule lacks the albumin-binding Drug Affinity Complex, its half-life is measured in tens of minutes rather than days. This enables researchers to simulate normal physiological pulsatile GH release spikes without inducing continuous receptor downregulation or receptor desensitization.

Preclinical data indicate that pulsatile administration of Modified GRF (1-29) leads to transient, proportional elevations in circulating growth hormone. Subsequent systemic downstream effects include upregulation of Insulin-like Growth Factor 1 (IGF-1) transcription in hepatic tissue. Investigators studying tissue regeneration, protein translation dynamics, and lipid oxidation pathways utilize this compound to analyze the downstream cascade of the GH/IGF-1 axis under controlled experimental parameters.

Comparative Analysis: GHRH Class Peptide Variations

When designing experiments involving growth hormone-releasing hormone analogs, selecting the correct structural derivative is essential for data fidelity. The primary distinction within this class centers around plasma half-life extension mechanisms and receptor clearance dynamics.

A comparative assessment of primary GHRH analogs includes:

- **CJC-1295 Without DAC (Modified GRF 1-29):** Features four amino acid substitutions that protect against enzymatic degradation. It exhibits an extended half-life relative to native GHRH (approx. 30 minutes in animal models), producing sharp, physiological pulses of GH release.

- **CJC-1295 With DAC:** Incorporates a lysine linker attached to a reactive maleimide group (Drug Affinity Complex). This moiety covalently binds to serum albumin in vivo, extending the biological half-life to several days and resulting in persistent, baseline GH and IGF-1 elevation.

- **Sermorelin:** Represents the unmodified N-terminal 29-amino-acid fragment of GHRH. While fully functional, it lacks the DPP-IV resistant substitutions, resulting in rapid enzymatic clearance (half-life of 8–12 minutes).

Co-Administration Research Protocols: Synergistic In Vitro Assays

In literature examining neuroendocrine regulation, researchers frequently evaluate the combined effects of GHRH analogs with growth hormone secretagogue receptor (GHSR-1a) agonists, such as Ipamorelin. These two distinct peptide classes operate through complementary intracellular pathways to regulate pituitary secretagogue activity.

While GHRH analogs increase cyclic AMP production through Gs-protein pathways, GHSR agonists trigger intracellular inositol trisphosphate (IP3) and diacylglycerol (DAG) pathways, releasing stored intracellular calcium. Preclinical studies indicate that simultaneous activation of both pathways yields a synergistic release of GH that exceeds the additive calculations of either peptide administered in isolation. Detailed protocols on dual-agent signaling kinetics are cataloged in our guide to GH secretagogue mechanisms.

Laboratory Reconstitution and Solution Handling Guidelines

CJC-1295 Without DAC 10mg is supplied as a sterile, lyophilized cake to maximize solid-state thermal stability during transit. To preserve molecular integrity during preparation, strict aseptic techniques and specific reconstitution reagents must be utilized inside a certified laminar flow hood.

Reconstitution protocols require the addition of Bacteriostatic Water (0.9% benzyl alcohol) or sterile water for injection, depending on the planned assay timeline. The diluent should be introduced slowly down the interior wall of the glass vial to prevent turbulent agitation. The vial should be gently swirled until complete dissolution occurs; shaking or rapid vortexing must be avoided to prevent mechanical shearing of the peptide chain. For exact calculations on concentration ratios, consult our interactive laboratory reconstitution calculator.

Quality Assurance, Purity Verification, and Lot Documentation

For scientific research to produce reproducible results, reagent purity and chemical consistency are paramount. Low-grade research peptides containing truncation sequences, residual synthesis reagents, or excess moisture disrupt quantitative assays and alter cellular response profiles.

PX1 Research enforces stringent quality control measures across all product lots. Analytical protocols include:

1. **Reverse-Phase HPLC (RP-HPLC):** Verifies chemical purity levels, guaranteeing target compound purity exceeds 98.0%.

2. **Electrospray Mass Spectrometry (ESI-MS):** Confirms exact molecular mass (3367.9 Da theoretical) to ensure complete amino acid sequence accuracy.

3. **Bacterial Endotoxin Testing:** Chromogenic LAL assays ensure endotoxin levels remain strictly below laboratory-grade thresholds (<0.5 EU/mg).

4. **Lot-Specific Traceability:** Every vial features a unique batch number linked directly to downloadable analytical documentation available to verified institutional procurement officers or via our wholesale laboratory account portal.

Storage and Thermal Stability Parameters

Lyophilized CJC-1295 Without DAC 10mg demonstrates stability at controlled room temperatures during short-term transit. However, upon arrival at the research facility, long-term storage parameters must be enforced to prevent hydrolysis or thermal degradation.

Unreconstituted lyophilized vials should be stored in a sub-zero freezer environment at -20°C or -80°C, protected from ambient light exposure. Under these conditions, the peptide remains stable for up to 24 months. Once reconstituted, liquid solutions must be kept refrigerated at 2°C to 8°C and utilized within 30 days. Multiple freeze-thaw cycles of liquid solutions must be strictly avoided, as thermal fluctuations break peptide bonds and induce irreversible protein aggregation.